EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation

Xiaohui Du, Congcong Zhang, Ying Li, Peipei He, Jian Wang, Xuena Chen, Han Wang, Qi Wang

MedComm – Oncology · 2025-03 · 4 (1)

DOI: 10.1002/mog2.70011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 28.01.2025. Verfasst von Xiaohui Du und 7 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osimertinib resistance remains a significant challenge in the treatment of non‐small cell lung cancer (NSCLC). N 6 ‐methyladenosine (m 6 A) modifications are closely linked to various mechanisms of anticancer resistance and autophagy, offering new avenues for targeted therapies. However, the role of m 6 A‐mediated autophagy in osimertinib‐resistant NSCLC is still unclear. In this study, we utilized multi‐omics sequencing analysis and found that overexpression of the m 6 A methyltransferase METTL3 contributes to osimertinib resistance in NSCLC. Importantly, we identified that METTL3 positively regulates the expression of the autophagy‐related gene ubiquinone‐cytochrome C reductase complex assembly factor 2 ( UQCC2 ) through an m 6 A‐dependent mechanism. Further, we confirmed that METTL3 knockdown leads to UQCC2 downregulation and triggers autophagy activation. Interestingly, lomitapide, a cholesterol‐lowering drug, was repurposed to enhance the sensitivity of cancer cells to therapy by inhibiting METTL3, which in turn activated autophagy‐associated cell death pathways, reversing osimertinib resistance. This study emphasizes the critical role of the METTL3/UQCC2 axis in autophagy‐mediated drug resistance and positions lomitapide as a promising METTL3 inhibitor and autophagy inducer with potential therapeutic effects, either alone or in combination with other anticancer agents, in patients with osimertinib‐resistant NSCLC.

Zitieren

APA

Du, X., Zhang, C., Li, Y., He, P., Wang, J., Chen, X., Wang, H., & Wang, Q. (2025). Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation. MedComm – Oncology, 4(1). https://doi.org/10.1002/mog2.70011

Vancouver

Du X, Zhang C, Li Y, He P, Wang J, Chen X, et al. Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation. MedComm – Oncology. 2025;4(1). doi:10.1002/mog2.70011

BibTeX
@article{Du2025,
  author = {Du, Xiaohui and Zhang, Congcong and Li, Ying and He, Peipei and Wang, Jian and Chen, Xuena and Wang, Han and Wang, Qi},
  title = {Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation},
  journal = {MedComm – Oncology},
  year = {2025},
  volume = {4},
  number = {1},
  doi = {10.1002/mog2.70011}
}
Kostenlos starten →